B-cell lymphoma-extra large (Bcl-xL)

B-cell lymphoma-extra large (Bcl-xL) is an anti-apoptotic member of the Bcl‑2 family encoded by the *BCL2-like 1* gene. It is a transmembrane protein primarily localized at mitochondria where it plays a central role in regulating cell death by inhibiting apoptosis. Mechanistically, it prevents mitochondrial outer membrane permeabilization by sequestering pro-apoptotic factors such as Bax/Bak or binding directly to cytochrome c residues, thus blocking caspase activation pathways that lead to programmed cell death. Beyond its canonical anti-apoptotic activity, Bcl-xL regulates other cellular processes including autophagy through interaction with Beclin 1; supports neuronal growth and synaptic plasticity; modulates calcium signaling; enhances ATP production; and contributes broadly to cellular metabolic efficiency. Overexpression or dysregulation is implicated in cancer progression—especially hematologic malignancies—and resistance to chemotherapy. Therapeutically, selective inhibition using small molecules known as BH3-mimetics has shown promise but comes with challenges such as on-target toxicity affecting platelets due to their dependence on this protein for survival[1][2][3][5].

Other names

BCL2-like 1Bcl-X(L)BCL-XLBcl-xl protein

Drugs targeting this molecule typically act by inhibiting its anti-apoptotic function, thereby promoting apoptosis in cancer cells. This is often achieved by mimicking the action of pro-apoptotic BH3-only proteins that bind to the hydrophobic groove on Bcl-xL, displacing it from pro-apoptotic partners like Bax/Bak, leading to mitochondrial outer membrane permeabilization and cell death[2][5].